Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases

Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Opukholi zhenskoĭ reproduktivnoĭ sistemy 2016-06, Vol.12 (1), p.46-51
Hauptverfasser: Dashyan, G. A., Semiglazov, V. F., Krivorot’ko, P. V., Semiglazova, T. Yu, Topuzov, E. E., Paltuev, R. M., Zernov, K. Yu, Apollonova, V. S., Ereshchenko, S. S., Petrova, A. V., Zhil’tsova, E. K., Ivanova, O. A.
Format: Artikel
Sprache:eng
Schlagworte:
central nervous system metastases
her-2-positve breast cancer
t-dm1
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of investigations substantiating the use of anti-HER-2 targeting agents, as well as the innovative agent T-DM1 to treat brain metastases.
ISSN:1994-4098
1999-8627
DOI:10.17650/1994-4098-2016-12-1-46-51